TrialJournal of Alzheimer's disease : JAD2020

An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer's Disease.

Stanley Chamberlain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.